Symbols / SRPT $17.09 +2.58%
SRPT Chart
About
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.79B |
| Enterprise Value | 1.85B | Income | -713.41M | Sales | 2.20B |
| Book/sh | 10.87 | Cash/sh | 8.95 | Dividend Yield | — |
| Payout | 0.00% | Employees | 835 | IPO | — |
| P/E | — | Forward P/E | 6.16 | PEG | — |
| P/S | 0.82 | P/B | 1.57 | P/C | — |
| EV/EBITDA | -3.02 | EV/Sales | 0.84 | Quick Ratio | 1.33 |
| Current Ratio | 2.32 | Debt/Eq | 91.14 | LT Debt/Eq | — |
| EPS (ttm) | -7.13 | EPS next Y | 2.77 | EPS Growth | — |
| Revenue Growth | -32.70% | Earnings | 2026-05-06 | ROA | -11.24% |
| ROE | -53.47% | ROIC | — | Gross Margin | -7.43% |
| Oper. Margin | -92.58% | Profit Margin | -32.45% | Shs Outstand | 104.99M |
| Shs Float | 91.78M | Short Float | 23.45% | Short Ratio | 8.87 |
| Short Interest | — | 52W High | 81.87 | 52W Low | 10.42 |
| Beta | 0.46 | Avg Volume | 2.70M | Volume | 854.62K |
| Target Price | $20.61 | Recom | Hold | Prev Close | $16.66 |
| Price | $17.09 | Change | 2.58% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.61
Mean price target
2. Current target
$16.84
Latest analyst target
3. DCF / Fair value
$16.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$16.84
Low
$5.00
High
$38.00
Mean
$20.61
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-13 | main | Mizuho | Outperform → Outperform | $31 |
| 2026-03-10 | main | Citigroup | Sell → Sell | $9 |
| 2026-03-02 | reit | HC Wainwright & Co. | Sell → Sell | $5 |
| 2026-02-27 | main | Wells Fargo | Overweight → Overweight | $38 |
| 2026-01-27 | reit | HC Wainwright & Co. | Sell → Sell | $5 |
| 2026-01-23 | main | Wedbush | Outperform → Outperform | $34 |
| 2026-01-14 | reit | HC Wainwright & Co. | Sell → Sell | $5 |
| 2025-12-09 | init | Wedbush | — → Outperform | $32 |
| 2025-11-05 | main | Barclays | Equal-Weight → Equal-Weight | $20 |
| 2025-11-05 | main | Wells Fargo | Overweight → Overweight | $45 |
| 2025-11-05 | main | Guggenheim | Buy → Buy | $19 |
| 2025-11-05 | up | Mizuho | Neutral → Outperform | $26 |
| 2025-11-04 | main | Baird | Neutral → Neutral | $15 |
| 2025-10-30 | main | Piper Sandler | Neutral → Neutral | $16 |
| 2025-09-22 | up | BMO Capital | Market Perform → Outperform | $50 |
| 2025-09-15 | reit | Guggenheim | Buy → Buy | $22 |
| 2025-09-09 | main | Leerink Partners | Market Perform → Market Perform | $15 |
| 2025-08-25 | reit | HC Wainwright & Co. | Sell → Sell | $5 |
| 2025-08-21 | main | B of A Securities | Underperform → Underperform | $16 |
| 2025-08-20 | main | B of A Securities | Underperform → Underperform | $17 |
- SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study - Yahoo Finance ue, 17 Mar 2026 14
- SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study - Zacks Investment Research ue, 17 Mar 2026 14
- Extra immune drug tested to limit liver damage in Duchenne gene therapy trial - Stock Titan Mon, 16 Mar 2026 12
- SRPT Stock Rises as DMD Gene Therapy Safety Trial Kicks Off - Bitget ue, 17 Mar 2026 00
- Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness - simplywall.st Sun, 15 Mar 2026 23
- Price-Driven Insight from (SRPT) for Rule-Based Strategy - Stock Traders Daily Mon, 16 Mar 2026 06
- Boxer Capital Management LLC Increases Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat Sun, 15 Mar 2026 11
- Sarepta Therapeutics (SRPT) Maintains 'Outperform' Rating as Miz - GuruFocus Fri, 13 Mar 2026 15
- Sarepta Therapeutics Stock Pre-Market (+4.7%): Rebounds With Market on Easing Geopolitical Fears - Trefis Sat, 07 Mar 2026 12
- 7.5-year Duchenne gene therapy data, caregiver views set for MDA 2026 - Stock Titan hu, 26 Feb 2026 08
- Sarepta Therapeutics (NASDAQ:SRPT) Director Sells $123,207.78 in Stock - MarketBeat Sat, 14 Mar 2026 01
- Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Yahoo Finance Sat, 28 Feb 2026 08
- Reporting person files to sell restricted SRPT shares (SRPT) - Stock Titan hu, 12 Mar 2026 20
- Braidwell LP Makes New Investment in Sarepta Therapeutics, Inc. $SRPT - MarketBeat Sun, 15 Mar 2026 08
- Tax withholding trims Sarepta (NASDAQ: SRPT) EVP's stock stake - Stock Titan Fri, 13 Mar 2026 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 7239 | 123208.0 | — | Sale at price 17.02 per share. | MAYO STEPHEN L. | Director | — | 2026-03-12 00:00:00 | D |
| 1 | 8125 | nan | — | — | RODINO-KLAPAC LOUISE | Officer | — | 2026-02-27 00:00:00 | D |
| 2 | 8125 | nan | — | — | ESTEPAN IAN MICHAEL | Chief Operating Officer | — | 2026-02-27 00:00:00 | D |
| 3 | 7450 | 102140.0 | — | Conversion of Exercise of derivative security at price 13.71 per share. | ESTEPAN IAN MICHAEL | Chief Operating Officer | — | 2026-02-26 00:00:00 | D |
| 4 | 10500 | 143955.0 | — | Conversion of Exercise of derivative security at price 13.71 per share. | NICAISE CLAUDE M.D. | Director | — | 2026-01-29 00:00:00 | D |
| 5 | 10500 | 143955.0 | — | Conversion of Exercise of derivative security at price 13.71 per share. | BEHRENS M KATHLEEN | Director | — | 2026-01-27 00:00:00 | D |
| 6 | 13187 | 294202.0 | — | Sale at price 22.31 per share. | ESTEPAN IAN MICHAEL | Chief Operating Officer | — | 2025-12-16 00:00:00 | D |
| 7 | 539084 | — | — | Stock Award(Grant) at price 0.00 per share. | INGRAM DOUGLAS S | Chief Executive Officer | — | 2025-12-05 00:00:00 | D |
| 8 | 143875 | — | — | Stock Award(Grant) at price 0.00 per share. | RODINO-KLAPAC LOUISE | Officer | — | 2025-09-03 00:00:00 | D |
| 9 | 143875 | — | — | Stock Award(Grant) at price 0.00 per share. | ESTEPAN IAN MICHAEL | Chief Operating Officer | — | 2025-09-03 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -8.62M | -768.12K | -87.96M | -25.48M |
| TaxRateForCalcs | 0.21 | 0.10 | 0.21 | 0.21 |
| NormalizedEBITDA | -578.50M | 324.73M | -34.84M | -473.54M |
| TotalUnusualItems | -41.06M | -7.84M | -418.85M | -121.32M |
| TotalUnusualItemsExcludingGoodwill | -41.06M | -7.84M | -418.85M | -121.32M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -713.41M | 235.24M | -535.98M | -703.49M |
| ReconciledDepreciation | 44.52M | 37.72M | 44.40M | 41.86M |
| ReconciledCostOfRevenue | 797.71M | 283.78M | 107.50M | 98.84M |
| EBITDA | -619.56M | 316.89M | -453.69M | -594.85M |
| EBIT | -664.09M | 279.17M | -498.09M | -636.72M |
| NetInterestIncome | -1.45M | 53.38M | 63.96M | -25.52M |
| InterestExpense | 38.14M | 18.39M | 22.01M | 53.25M |
| InterestIncome | 36.69M | 71.77M | 85.97M | 27.72M |
| NormalizedIncome | -680.97M | 242.31M | -205.09M | -607.65M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -713.41M | 235.24M | -535.98M | -703.49M |
| TotalExpenses | 2.86B | 1.68B | 1.51B | 1.47B |
| TotalOperatingIncomeAsReported | -699.78M | 218.08M | -267.82M | -536.20M |
| DilutedAverageShares | 100.12M | 107.88M | 92.40M | 87.56M |
| BasicAverageShares | 100.12M | 95.08M | 92.40M | 87.56M |
| DilutedEPS | -7.13 | 2.34 | -5.80 | -8.03 |
| BasicEPS | -7.13 | 2.47 | -5.80 | -8.03 |
| DilutedNIAvailtoComStockholders | -713.41M | 235.24M | -535.98M | -703.49M |
| NetIncomeCommonStockholders | -713.41M | 235.24M | -535.98M | -703.49M |
| NetIncome | -713.41M | 235.24M | -535.98M | -703.49M |
| NetIncomeIncludingNoncontrollingInterests | -713.41M | 235.24M | -535.98M | -703.49M |
| NetIncomeContinuousOperations | -713.41M | 235.24M | -535.98M | -703.49M |
| TaxProvision | 11.19M | 25.54M | 15.88M | 13.53M |
| PretaxIncome | -702.23M | 260.77M | -520.10M | -689.96M |
| OtherIncomeExpense | -43.00M | -10.68M | -316.23M | -128.24M |
| OtherNonOperatingIncomeExpenses | -1.94M | -2.85M | 102.62M | -6.92M |
| SpecialIncomeCharges | -25.15M | -7.84M | -418.85M | -121.32M |
| GainOnSaleOfPPE | 0.00 | 102.00M | ||
| OtherSpecialCharges | -16.86M | 387.33M | 125.44M | 10.00M |
| WriteOff | 0.00 | 0.00 | 30.32M | 2.58M |
| ImpairmentOfCapitalAssets | 4.49M | |||
| RestructuringAndMergernAcquisition | 42.01M | 7.84M | 1.20M | -6.70M |
| SecuritiesAmortization | -11.23M | -157.00K | ||
| GainOnSaleOfSecurity | -15.91M | -2.79M | 1.53M | |
| NetNonOperatingInterestIncomeExpense | -1.45M | 53.38M | 63.96M | -25.52M |
| InterestExpenseNonOperating | 38.14M | 18.39M | 22.01M | 53.25M |
| InterestIncomeNonOperating | 36.69M | 71.77M | 85.97M | 27.72M |
| OperatingIncome | -657.77M | 218.08M | -267.82M | -536.20M |
| OperatingExpense | 2.02B | 1.36B | 1.36B | 1.33B |
| DepreciationAmortizationDepletionIncomeStatement | 2.62M | 2.40M | 1.56M | 714.00K |
| DepreciationAndAmortizationInIncomeStatement | 2.62M | 2.40M | 1.56M | 714.00K |
| Amortization | 2.62M | 2.40M | 1.56M | 714.00K |
| AmortizationOfIntangiblesIncomeStatement | 2.62M | 2.40M | 1.56M | 714.00K |
| ResearchAndDevelopment | 1.52B | 804.52M | 877.39M | 877.09M |
| SellingGeneralAndAdministration | 491.72M | 557.87M | 481.87M | 451.42M |
| GeneralAndAdministrativeExpense | 491.72M | 557.87M | 481.87M | 451.42M |
| OtherGandA | 262.27M | 276.07M | 224.53M | 157.57M |
| SalariesAndWages | 229.45M | 281.80M | 257.34M | 293.85M |
| GrossProfit | 1.36B | 1.58B | 1.09B | 793.02M |
| CostOfRevenue | 839.61M | 319.10M | 150.34M | 139.99M |
| TotalRevenue | 2.20B | 1.90B | 1.24B | 933.01M |
| OperatingRevenue | 2.20B | 1.90B | 1.24B | 933.01M |
| Line Item | 2025-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 650.88K | |||
| OrdinarySharesNumber | 104.96M | 96.90M | 93.73M | 87.95M |
| ShareIssued | 105.62M | 96.90M | 93.73M | 87.95M |
| NetDebt | 27.69M | 34.11M | 809.57M | 577.51M |
| TotalDebt | 1.04B | 1.34B | 1.40B | 1.62B |
| TangibleBookValue | 1.11B | 1.50B | 829.72M | 377.37M |
| InvestedCapital | 1.97B | 2.66B | 2.10B | 1.93B |
| WorkingCapital | 1.44B | 2.34B | 1.93B | 1.94B |
| NetTangibleAssets | 1.11B | 1.50B | 829.72M | 377.37M |
| CapitalLeaseObligations | 210.77M | 205.95M | 158.81M | 73.07M |
| CommonStockEquity | 1.14B | 1.53B | 859.34M | 384.95M |
| TotalCapitalization | 1.97B | 2.66B | 1.99B | 1.93B |
| TotalEquityGrossMinorityInterest | 1.14B | 1.53B | 859.34M | 384.95M |
| StockholdersEquity | 1.14B | 1.53B | 859.34M | 384.95M |
| GainsLossesNotAffectingRetainedEarnings | 272.00K | -218.00K | 918.00K | -1.66M |
| OtherEquityAdjustments | 272.00K | -218.00K | 918.00K | -1.66M |
| TreasuryStock | 25.26M | 0.00 | ||
| RetainedEarnings | -4.88B | -4.21B | -4.45B | -3.91B |
| AdditionalPaidInCapital | 6.04B | 5.74B | 5.30B | 4.30B |
| CapitalStock | 11.00K | 10.00K | 9.00K | 9.00K |
| CommonStock | 11.00K | 10.00K | 9.00K | 9.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.21B | 2.44B | 2.41B | 2.74B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.11B | 1.70B | 1.75B | 2.12B |
| OtherNonCurrentLiabilities | 1.53M | 49.15M | 41.10M | 36.94M |
| NonCurrentDeferredLiabilities | 83.91M | 325.00M | 437.00M | 485.00M |
| NonCurrentDeferredRevenue | 83.91M | 325.00M | 437.00M | 485.00M |
| LongTermDebtAndCapitalLeaseObligation | 1.03B | 1.33B | 1.27B | 1.60B |
| LongTermCapitalLeaseObligation | 199.38M | 192.47M | 140.97M | 57.58M |
| LongTermDebt | 828.97M | 1.14B | 1.13B | 1.54B |
| CurrentLiabilities | 1.10B | 731.68M | 653.66M | 619.60M |
| OtherCurrentLiabilities | 15.49M | 15.05M | ||
| CurrentDeferredLiabilities | 443.40M | 130.26M | 50.42M | 89.24M |
| CurrentDeferredRevenue | 443.40M | 130.26M | 50.42M | 89.24M |
| CurrentDebtAndCapitalLeaseObligation | 11.39M | 13.47M | 123.33M | 15.49M |
| CurrentCapitalLeaseObligation | 11.39M | 13.47M | 17.84M | 15.49M |
| CurrentDebt | 105.48M | |||
| OtherCurrentBorrowings | 105.48M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 58.61M | 91.12M | 78.73M | 65.95M |
| CurrentProvisions | 117.52M | 109.16M | 100.08M | 68.78M |
| PayablesAndAccruedExpenses | 464.38M | 387.68M | 301.11M | 380.14M |
| CurrentAccruedExpenses | 178.78M | 155.85M | 122.42M | 271.75M |
| InterestPayable | 20.71M | 4.19M | 4.39M | 4.96M |
| Payables | 285.60M | 231.83M | 178.68M | 108.40M |
| TotalTaxPayable | 4.75M | 17.39M | 13.77M | 12.52M |
| IncomeTaxPayable | 4.75M | 17.39M | 13.77M | 12.52M |
| AccountsPayable | 280.84M | 214.44M | 164.92M | 95.88M |
| TotalAssets | 3.35B | 3.96B | 3.26B | 3.13B |
| TotalNonCurrentAssets | 811.76M | 889.71M | 685.25M | 570.50M |
| OtherNonCurrentAssets | 202.86M | 206.96M | 212.32M | 183.65M |
| NonCurrentPrepaidAssets | 95.95M | 30.34M | 79.67M | 102.96M |
| NonCurrentDeferredAssets | 2.82M | 2.25M | ||
| NonCurrentDeferredTaxesAssets | 2.82M | 2.25M | ||
| InvestmentsAndAdvances | 10.57M | 136.87M | 6.53M | 31.32M |
| OtherInvestments | 10.57M | 136.87M | 6.53M | 31.32M |
| GoodwillAndOtherIntangibleAssets | 28.95M | 26.89M | 29.62M | 7.58M |
| OtherIntangibleAssets | 28.95M | 26.89M | 29.62M | 7.58M |
| NetPPE | 470.62M | 488.65M | 357.11M | 244.99M |
| AccumulatedDepreciation | -280.92M | -234.15M | -190.97M | -148.88M |
| GrossPPE | 751.53M | 722.79M | 548.08M | 393.87M |
| Leases | 349.73M | 155.07M | 99.99M | 97.33M |
| ConstructionInProgress | 5.58M | 165.90M | 91.09M | 23.59M |
| OtherProperties | 260.81M | 278.19M | 238.05M | 156.76M |
| MachineryFurnitureEquipment | 73.03M | 62.28M | 60.71M | 58.08M |
| BuildingsAndImprovements | 52.23M | 51.18M | 48.06M | 47.94M |
| LandAndImprovements | 10.17M | 10.17M | 10.17M | 10.17M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.54B | 3.07B | 2.58B | 2.56B |
| OtherCurrentAssets | 9.20M | 9.21M | 12.48M | 6.82M |
| PrepaidAssets | 154.73M | 309.77M | 130.77M | 96.10M |
| Inventory | 914.74M | 749.96M | 322.86M | 203.97M |
| Receivables | 519.61M | 649.73M | 436.98M | 261.60M |
| OtherReceivables | 104.12M | 34.61M | 29.79M | 41.76M |
| TaxesReceivable | 15.60M | 13.13M | 6.86M | 1.90M |
| AccruedInterestReceivable | 1.66M | 1.97M | 2.73M | 3.31M |
| AccountsReceivable | 398.23M | 601.99M | 400.33M | 214.63M |
| CashCashEquivalentsAndShortTermInvestments | 939.65M | 1.35B | 1.68B | 1.99B |
| OtherShortTermInvestments | 138.37M | 251.78M | 1.25B | 1.02B |
| CashAndCashEquivalents | 801.28M | 1.10B | 428.43M | 966.78M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -315.33M | -352.74M | -588.34M | -357.60M |
| RepurchaseOfCapitalStock | -25.01M | 0.00 | 0.00 | |
| RepaymentOfDebt | -162.59M | -68.00K | 0.00 | -823.23M |
| IssuanceOfDebt | 0.00 | 0.00 | 1.13B | 0.00 |
| IssuanceOfCapitalStock | 20.00M | 0.00 | 0.00 | 0.00 |
| CapitalExpenditure | -109.85M | -146.96M | -87.34M | -32.25M |
| InterestPaidSupplementalData | 14.91M | 15.86M | 15.92M | 44.42M |
| IncomeTaxPaidSupplementalData | 37.63M | 22.59M | 15.08M | 1.70M |
| EndCashPosition | 814.41M | 1.12B | 444.01M | 985.80M |
| BeginningCashPosition | 1.12B | 444.01M | 985.80M | 2.13B |
| ChangesInCash | -304.18M | 674.58M | -541.79M | -1.14B |
| FinancingCashFlow | -168.34M | 124.81M | 125.00M | 232.51M |
| CashFlowFromContinuingFinancingActivities | -168.34M | 124.81M | 125.00M | 232.51M |
| NetOtherFinancingCharges | -19.45M | -6.89M | -716.00K | -7.76M |
| ProceedsFromStockOptionExercised | 18.70M | 124.87M | 131.89M | -70.94M |
| NetCommonStockIssuance | -5.01M | 0.00 | 0.00 | 0.00 |
| CommonStockPayments | -25.01M | 0.00 | 0.00 | |
| CommonStockIssuance | 20.00M | 0.00 | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -162.59M | -68.00K | 0.00 | 304.17M |
| NetLongTermDebtIssuance | -162.59M | -68.00K | 0.00 | 304.17M |
| LongTermDebtPayments | -162.59M | -68.00K | 0.00 | -823.23M |
| LongTermDebtIssuance | 0.00 | 0.00 | 1.13B | 0.00 |
| InvestingCashFlow | 69.64M | 755.56M | -165.80M | -1.05B |
| CashFlowFromContinuingInvestingActivities | 69.64M | 755.56M | -165.80M | -1.05B |
| NetOtherInvestingChanges | 102.00M | -2.43M | 102.00M | |
| NetInvestmentPurchaseAndSale | 5.39M | 902.52M | -180.46M | -1.01B |
| SaleOfInvestment | 295.87M | 2.00B | 1.87B | 923.22M |
| PurchaseOfInvestment | -290.48M | -1.10B | -2.05B | -1.94B |
| NetBusinessPurchaseAndSale | 174.09M | 0.00 | 0.00 | 0.00 |
| SaleOfBusiness | 174.09M | 0.00 | 0.00 | |
| PurchaseOfBusiness | 0.00 | |||
| NetIntangiblesPurchaseAndSale | -7.88M | -10.00M | -11.24M | -1.43M |
| PurchaseOfIntangibles | -7.88M | -10.00M | -11.24M | -1.43M |
| NetPPEPurchaseAndSale | -101.97M | -136.96M | -76.11M | -30.82M |
| PurchaseOfPPE | -101.97M | -136.96M | -76.11M | -30.82M |
| OperatingCashFlow | -205.48M | -205.79M | -500.99M | -325.35M |
| CashFlowFromContinuingOperatingActivities | -205.48M | -205.79M | -500.99M | -325.35M |
| ChangeInWorkingCapital | 78.04M | -716.61M | -481.09M | -39.47M |
| ChangeInOtherWorkingCapital | 72.05M | -32.16M | -86.83M | -89.24M |
| ChangeInOtherCurrentAssets | -79.78M | -9.68M | 1.81M | -27.94M |
| ChangeInPayablesAndAccruedExpense | 104.27M | 110.65M | -50.13M | 147.57M |
| ChangeInPayable | 104.27M | 110.65M | -50.13M | 147.57M |
| ChangeInAccountPayable | 104.27M | 110.65M | -50.13M | 147.57M |
| ChangeInPrepaidAssets | 78.84M | -188.59M | -12.52M | 42.56M |
| ChangeInInventory | -301.09M | -395.17M | -147.71M | -50.78M |
| ChangeInReceivables | 203.75M | -201.66M | -185.70M | -61.64M |
| ChangesInAccountReceivables | 203.75M | -201.66M | -185.70M | -61.64M |
| OtherNonCashItems | 70.59M | 69.83M | -98.01M | 19.33M |
| StockBasedCompensation | 123.40M | 184.30M | 182.51M | 233.02M |
| AssetImpairmentCharge | 182.30M | 0.00 | 30.32M | 2.58M |
| AmortizationOfSecurities | -5.29M | -40.28M | -46.18M | -10.65M |
| DepreciationAmortizationDepletion | 44.52M | 37.72M | 44.40M | 41.86M |
| DepreciationAndAmortization | 44.52M | 37.72M | 44.40M | 41.86M |
| OperatingGainsLosses | 14.38M | 24.00M | 403.02M | 131.48M |
| EarningsLossesFromEquityInvestments | 17.29M | 0.00 | 0.00 | |
| GainLossOnInvestmentSecurities | 7.84M | 1.20M | -6.70M | |
| GainLossOnSaleOfPPE | 13.95M | 16.17M | 14.49M | 12.73M |
| NetIncomeFromContinuingOperations | -713.41M | 235.24M | -535.98M | -703.49M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SRPT
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|